Clinical Characteristics and Treatment Allocations in Patients with Myelodysplastic Syndromes and Monosomy 7: Results from an International Multicenter Study Suggest That Hypomethylating Agents Significantly Improve Overall- and AML-Free Survival in Patients Classified As Very High Risk By IPSS-R

Introduction: Total (-7) or partial (7q-) monosomy 7 is the second frequent abnormality in MDS, occurring in around 12% of MDS/AML and up to 40% of therapy-associated MDS/AML. The present study was designed to analyze clinical features, prognosis and response to different therapeutic strategies in p...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2014-12, Vol.124 (21), p.4656-4656
Main Authors: Schanz, Julie, Braulke, Friederike, Mufti, Ghulam J., Crisà, Elena, Kulasekararaj, Austin, Nachtkamp, Kathrin, Germing, Ulrich, Schmitz, Stefan, Haas, Peter, Lübbert, Michael, Müller-Thomas, Catharina, Götze, Katharina, Platzbecker, Uwe, Nolte, Florian, Hofmann, Wolf-Karsten, Haase, Detlef
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction: Total (-7) or partial (7q-) monosomy 7 is the second frequent abnormality in MDS, occurring in around 12% of MDS/AML and up to 40% of therapy-associated MDS/AML. The present study was designed to analyze clinical features, prognosis and response to different therapeutic strategies in patients with -7 or del(7q) in a multicentric, retrospective cohort study. Patients and Methods: 471 patients with MDS/AML following MDS and monosomy 7 were registered and retrospectively analyzed. The median observation time was 3.6 years. Inclusion criteria were defined as follows: Morphologic diagnosis of MDS/AML following MDS, bone marrow blast count
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V124.21.4656.4656